Current PD-L1 immunohistochemistry for non-small cell lung cancer

doi:10.21037/jtd.2018.02.38

Editorial

. 2018 Mar;10(3):1217-1219.

doi: 10.21037/jtd.2018.02.38.

Current PD-L1 immunohistochemistry for non-small cell lung cancer

Andreas H Scheel¹, Stephan C Schäfer¹

Affiliations

PMID: 29708172
PMCID: PMC5906363
DOI: 10.21037/jtd.2018.02.38

Editorial

Current PD-L1 immunohistochemistry for non-small cell lung cancer

Andreas H Scheel et al. J Thorac Dis. 2018 Mar.

. 2018 Mar;10(3):1217-1219.

doi: 10.21037/jtd.2018.02.38.

Authors

Andreas H Scheel¹, Stephan C Schäfer¹

Affiliation

¹ Institute of Pathology, University Hospital Cologne, Cologne, Germany.

PMID: 29708172
PMCID: PMC5906363
DOI: 10.21037/jtd.2018.02.38

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Scheel AH has collaborations with NordiQC (Aalborg, Denmark) and QuIP (Berlin, Germany) and has participated in advisory boards for Roche Pharmaceuticals, Bristol-Myers Squibb and Merck Sharp & Dohme within the past twelve months. Schäfer SC has no conflicts of interest to declare.

Comment on

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS. Büttner R, et al. J Clin Oncol. 2017 Dec 1;35(34):3867-3876. doi: 10.1200/JCO.2017.74.7642. Epub 2017 Oct 20. J Clin Oncol. 2017. PMID: 29053400 Review.

Cited by

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
Incorvaia L, Fanale D, Badalamenti G, Barraco N, Bono M, Corsini LR, Galvano A, Gristina V, Listì A, Vieni S, Gori S, Bazan V, Russo A. Incorvaia L, et al. Adv Ther. 2019 Oct;36(10):2600-2617. doi: 10.1007/s12325-019-01057-7. Epub 2019 Aug 20. Adv Ther. 2019. PMID: 31432460 Free PMC article. Review.
Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies.
Lawson NL, Dix CI, Scorer PW, Stubbs CJ, Wong E, Hutchinson L, McCall EJ, Schimpl M, DeVries E, Walker J, Williams GH, Hunt J, Barker C. Lawson NL, et al. Mod Pathol. 2020 Apr;33(4):518-530. doi: 10.1038/s41379-019-0372-z. Epub 2019 Sep 26. Mod Pathol. 2020. PMID: 31558782 Free PMC article.
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
Oellerich T, Schneider C, Thomas D, Knecht KM, Buzovetsky O, Kaderali L, Schliemann C, Bohnenberger H, Angenendt L, Hartmann W, Wardelmann E, Rothenburger T, Mohr S, Scheich S, Comoglio F, Wilke A, Ströbel P, Serve H, Michaelis M, Ferreirós N, Geisslinger G, Xiong Y, Keppler OT, Cinatl J Jr. Oellerich T, et al. Nat Commun. 2019 Aug 2;10(1):3475. doi: 10.1038/s41467-019-11413-4. Nat Commun. 2019. PMID: 31375673 Free PMC article.
Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.
Li JX, Huang JM, Jiang ZB, Li RZ, Sun A, Lai-Han Leung E, Yan PY. Li JX, et al. Integr Cancer Ther. 2019 Jan-Dec;18:1534735419890020. doi: 10.1177/1534735419890020. Integr Cancer Ther. 2019. PMID: 31838881 Free PMC article. Review.
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H, Ma N, Wang Y, Li H, Liu X, Su Y, Yang J. Sui H, et al. J Immunol Res. 2018 Aug 8;2018:6984948. doi: 10.1155/2018/6984948. eCollection 2018. J Immunol Res. 2018. PMID: 30159341 Free PMC article. Review.

See all "Cited by" articles

References

1. Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017;390:1853-62. 10.1016/S0140-6736(17)31601-X - DOI - PubMed
1. Tsao MS, Kerr KM, Dacic S, et al., editors. IASLC Atlas of PD-L1 Immunohistochemistry testing in lung cancer, 1st edition 2017. International Association for the Study of Lung Cancer, Aurora, USA.
1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
1. Büttner R, Gosney JR, Skov BG, et al. PD-L1 immunohistochemistry testing: a review on analytical assays and clinical implementation in non-small cell lung cancer. J Clin Oncol 2017;35:3867-76. 10.1200/JCO.2017.74.7642 - DOI - PubMed
1. NordiQC results for quality assessment of PD-L1 in NSCLC, run 'C1' 2017, retrieved 2018-01-10. Available online: http://www.nordiqc.org/downloads/assessments/96_102.pdf

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017;390:1853-62. 10.1016/S0140-6736(17)31601-X - DOI - PubMed

[2] Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017;390:1853-62. 10.1016/S0140-6736(17)31601-X - DOI - PubMed

[3] Tsao MS, Kerr KM, Dacic S, et al., editors. IASLC Atlas of PD-L1 Immunohistochemistry testing in lung cancer, 1st edition 2017. International Association for the Study of Lung Cancer, Aurora, USA.

[4] Tsao MS, Kerr KM, Dacic S, et al., editors. IASLC Atlas of PD-L1 Immunohistochemistry testing in lung cancer, 1st edition 2017. International Association for the Study of Lung Cancer, Aurora, USA.

[5] Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed

[6] Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed

[7] Büttner R, Gosney JR, Skov BG, et al. PD-L1 immunohistochemistry testing: a review on analytical assays and clinical implementation in non-small cell lung cancer. J Clin Oncol 2017;35:3867-76. 10.1200/JCO.2017.74.7642 - DOI - PubMed

[8] Büttner R, Gosney JR, Skov BG, et al. PD-L1 immunohistochemistry testing: a review on analytical assays and clinical implementation in non-small cell lung cancer. J Clin Oncol 2017;35:3867-76. 10.1200/JCO.2017.74.7642 - DOI - PubMed

[9] NordiQC results for quality assessment of PD-L1 in NSCLC, run 'C1' 2017, retrieved 2018-01-10. Available online: http://www.nordiqc.org/downloads/assessments/96_102.pdf

[10] NordiQC results for quality assessment of PD-L1 in NSCLC, run 'C1' 2017, retrieved 2018-01-10. Available online: http://www.nordiqc.org/downloads/assessments/96_102.pdf

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Current PD-L1 immunohistochemistry for non-small cell lung cancer

Affiliation

Current PD-L1 immunohistochemistry for non-small cell lung cancer

Authors

Affiliation

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials